LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Strona główna・Stock List・Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Closed

Sector Healthcare

1,130.9 -1.48

Buy Sell

Overview

Share price change

24h

Current

Min

1129.97

Max

1135.51

Key metrics
By Trading Economics
Income	710M 1.4B
Sales	400M 3.6B
P/E Sector Avg	31.03 103.001
EPS	11.56
Profit margin	40.346
Employees	13,450
EBITDA	933M 1.8B

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+4.43 upside

Dividends
By Dow Jones
Next Earnings	31 paź 2024

Market Stats
By TradingEconomics
Market Cap	130B
Previous open	1132.38
Previous close	1130.9

News Sentiment

By Acuity

38%

62%

82 / 365 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

N/A / 1199.12 Support & Resistance

Regeneron Pharmaceuticals Inc Chart

Related News

8 lip 2024, 12:00 UTC

Earnings

Regeneron Expects Earnings Hit After $24 Million R&D Charge

2 maj 2024, 11:02 UTC

Earnings

Regeneron Pharmaceuticals 1Q Revenue Declines Amid Lower EYLEA Sales

2 lut 2024, 11:59 UTC

Earnings

Regeneron's 4Q Sales Edge Higher, Despite Softening Demand for Covid Products

1 sie 2024, 11:50 UTC

Earnings

Regeneron Stock Climbs After Strong Second-Quarter Performance -- IBD

1 sie 2024, 10:37 UTC

Earnings

Regeneron Pharma 2Q Adj EPS $11.56 >REGN

1 sie 2024, 10:30 UTC

Earnings

Regeneron Pharma 2Q EPS $12.41 >REGN

1 sie 2024, 10:30 UTC

Earnings

Regeneron Pharma 2Q Net $1.43B >REGN

1 sie 2024, 10:30 UTC

Earnings

Regeneron Pharma 2Q Rev $3.55B >REGN

20 cze 2024, 20:16 UTC

Top News

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20 cze 2024, 18:09 UTC

Top News

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20 cze 2024, 11:00 UTC

Top News

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- WSJ

2 maj 2024, 10:32 UTC

Earnings

Regeneron Pharma Cuts 2024 Capital Spending View to $780M-$880M From $825M-$950M >REGN

2 maj 2024, 10:32 UTC

Earnings

Regeneron Pharma Still Sees 2024 Adjusted Gross Margin 89%-91% >REGN

2 maj 2024, 10:31 UTC

Earnings

Regeneron Pharma Sets New $3 Billion Share-Repurchase Program >REGN

2 maj 2024, 10:30 UTC

Earnings

Regeneron Pharma 1Q Rev $3.15B >REGN

2 maj 2024, 10:30 UTC

Earnings

Regeneron Pharma 1Q Adj EPS $9.55 >REGN

2 maj 2024, 10:30 UTC

Earnings

Regeneron Pharma 1Q EPS $6.27 >REGN

2 maj 2024, 10:30 UTC

Earnings

Regeneron Pharma 1Q Net $722M >REGN

11 kwi 2024, 13:47 UTC

Hot Stocks

Stocks to Watch Thursday: Robinhood, Alpine Immune, Constellation Brands -- WSJ

5 lut 2024, 12:00 UTC

Top News

What a $200 Billion Blockbuster Drug Reveals About Big Pharma's Playbook -- Heard on the Street -- WSJ

2 lut 2024, 17:05 UTC

Earnings

Regeneron Earnings Beat Forecasts as Sales of Updated Eye Drug Raise Hopes -- Barrons.com

2 lut 2024, 14:13 UTC

Earnings

The Surprising Sources Of Regeneron's Fourth-Quarter Beat As Shares Hit Another Record High -- IBD

2 lut 2024, 11:36 UTC

Earnings

Regeneron Pharma Sees 2024 Capital Spending $825M-$950M >REGN

2 lut 2024, 11:36 UTC

Earnings

Regeneron Pharma Sees 2024 Adjusted Gross Margin 89%-91% >REGN

2 lut 2024, 11:36 UTC

Earnings

Regeneron Pharma Sees 2024 Adjusted R&D Spending $4.3B-$4.5B >REGN

2 lut 2024, 11:31 UTC

Earnings

Regeneron Pharma: 4Q Dupixent Global Sales, Recorded by Sanofi, Rose 31% to $3.22B >REGN

2 lut 2024, 11:31 UTC

Earnings

Regeneron Pharma 4Q U.S. Eylea HD, Eylea Sales $1.46B >REGN

2 lut 2024, 11:30 UTC

Earnings

Regeneron Pharma 4Q EPS $10.19 >REGN

2 lut 2024, 11:30 UTC

Earnings

Regeneron Pharma 4Q Rev $3.43B >REGN

2 lut 2024, 09:37 UTC

Earnings

These Stocks Are Moving the Most Today: Meta, Amazon, Apple, Intel, Deckers, Skechers, Clorox, and More -- Barrons.com

Peer Comparison

Price change

Regeneron Pharmaceuticals Inc Forecast

Price Target

By TipRanks

4.43% upside

12 Months Forecast

Average 1,181.61 USD 4.43%

High 1,292 USD

Low 870 USD

Based on 19 Wall Street analysts offering 12 month price targets forRegeneron Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

19 ratings

Buy

Hold

Sell

Based on 19 analysts giving stock ratings to Regeneron Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

N/A / 1199.12Support & Resistance

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

82 / 365 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company commercializes medicines and product candidates for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.